Add Formweb to your mobile device
System Formulary Update
Contraceptives Class Standardization
Situation:
Contraceptives – Long-Acting Inserts and Injectables Combinations class review standardization was approved for addition to the health system formulary at the September 2023 System Pharmacy and Therapeutics Committee Meeting.
Background:
The following products were reviewed: Levonorgestrel 21 mcg/24 h 52 mg intrauterine device, Medroxyprogesterone 150 mg/1 mL intramuscular syringe, Medroxyprogesterone 104 mg/0.65 mL subcutaneous syringe, Etonogestrel 68 mg subdermal implant, Medroxyprogesterone 150 mg/mL intramuscular suspension (1 mL vial), Levonorgestrel 20.4 mg/24 h 52 mg intrauterine device, Levonorgestrel 19.5 mcg/24 h intrauterine device, Levonorgestrel 14 mcg/24 h 13.5 mg intrauterine device, Copper intrauterine device.
Assessment/Recommendations:
System P&T voted to include the following product from the UNC Health Medication Formulary:
- Etonogestrel 68 mg subdermal implant
- Medroxyprogesterone 150 mg/mL intramuscular suspension (1 mL vial)
- Levonorgestrel 20.4 mg/24 h 52 mg intrauterine device (LILETTA)
- Levonorgestrel 19.5 mcg/24 h intrauterine device (KYLEENA)
- Levonorgestrel 14 mcg/24 h 13.5 mg intrauterine device (SKYLA)
- Copper intrauterine device (PARAGARD)
Note: Stock of this formulary product may vary at individual entities
Formulary/Epic Changes will Go-Live on Tuesday, December 5, 2023